Latest News and Press Releases

The Opticyte Tears program uses patients’ blood serum to create Autologous Serum Tears from the convenience of their homes.

RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Merakris Therapeutics has added two new executives to its leadership team as it prepares to expand its product line and increase its...

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- A review published recently in the international scientific journal Biomedicines highlights the therapeutic benefits of amniotic fluid...

RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) -- A recently published manuscript containing research sponsored, in part, by Merakris Therapeutics has opened the door to more...

RESEARCH TRIANGLE PARK, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- The first patient has been enrolled in a Phase II clinical trial – sponsored by Merakris Therapeutics – to measure the safety and...

RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- About five years ago, the U.S. Food and Drug Administration (FDA) announced plans to toughen its guidelines around the development and...

RESEARCH TRIANGLE PARK, N.C., June 02, 2022 (GLOBE NEWSWIRE) -- A peer-reviewed case study in the May 21 edition of SAGE Open Medical Case Reports highlights the effectiveness of two Merakris...

RESEARCH TRIANGLE PARK, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Opticyte® Amniotic Ocular Matrix, a product of Research Triangle Park-based Merakris Therapeutics, has gotten the attention of a...

RESEARCH TRIANGLE PARK, N.C., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United...

RESEARCH TRIANGLE PARK, N.C., July 20, 2021 (GLOBE NEWSWIRE) -- Research Triangle Park-based biotechnology company Merakris Therapeutics has reached an agreement with Miracles In Sight (MIS) to...